Treatment for cocaine dependence

Treatment for cocaine dependence

Brief description of study

A PHASE II, DOUBLE-BLIND, PLACEBO-CONTROLLED, TRIAL OF NS2359 FOR THE TREATMENT OF COCAINE DEPENDENCE If you suffer from cocaine dependence, a new clinical research study is available for you. The purpose of this research study is to test whether the drug, NS2359, is useful and safe for treating cocaine dependence.

Detailed description of study

If you suffer from cocaine dependence, a new clinical research study is available for you. The purpose of this research study is to test whether the drug, NS2359, is useful and safe for treating cocaine dependence. In this clinical research study, you will receive medication that is either NS2359 or placebo over a period of 8 weeks. As a participant of this study, you will not know if you are getting the real medication or the placebo. However, it is important to remember that you will be under a doctor’s care throughout the duration of the study. The TRC staff does not know which medication you are taking. The maximum duration for one subject is 13 weeks. These 13 weeks consist of up to 4 weeks of screening (called study week 1), a randomized medication phase (NS2359 or placebo) that lasts for 8 weeks (study weeks 2-9), and an end of study visit (week 13). During the screening phase and your 8 weeks of outpatient treatment, you are asked to come to the TRC 3 times each week. Each visit will last anywhere from 15 minutes to 2 hours depending on the number of appointments you have that day. A urine sample will be collected at every visit.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Addictive Behavior,Drug dependence,Smoking,Cocaine-Related Disorders,drugs,cocaine
  • Age: Between 18 Years - 70 Years
  • Gender: All
Updated on 29 Jun 2023. Study ID: 824109

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center